Medicine and Dentistry
Radiation Therapy
100%
Prostate Cancer
54%
Proton Therapy
45%
Overall Survival
44%
Non Small Cell Lung Cancer
42%
Neoplasm
36%
Disease
30%
Stereotactic Body Radiation Therapy
29%
Lung Cancer
27%
Malignant Neoplasm
24%
Chemoradiotherapy
19%
Metastatic Carcinoma
17%
Intensity Modulated Radiation Therapy
16%
Radiation Oncology
15%
Chemotherapy
14%
Hazard Ratio
13%
Immunotherapy
12%
Lung Metastasis
12%
Bone Metastasis
11%
Recurrent Disease
11%
Brachytherapy
10%
Clinical Trial
10%
Lung
10%
Androgen Deprivation Therapy
10%
Pembrolizumab
10%
Disease Free Survival
10%
Progression Free Survival
9%
Adenocarcinoma
9%
Arm
9%
Magnetic Resonance Imaging
8%
Low Drug Dose
8%
Esophagitis
8%
Cytomegalovirus
7%
Transplantation
7%
Systemic Therapy
7%
External Beam Radiotherapy
7%
Survival Rate
7%
Clear Cell Renal Cell Carcinoma
7%
Bladder
7%
Cancer Therapy
6%
Proportional Hazards Model
6%
Drug Megadose
6%
Odds Ratio
6%
Small Cell Lung Cancer
6%
Positron Emission Tomography-Computed Tomography
5%
Oncology
5%
Quality of Life
5%
Phase II Trials
5%
Non-Small Cell Lung Cancer
5%
Radiation Pneumonia
5%
Keyphrases
Non-small Cell Lung Cancer (NSCLC)
41%
Overall Survival
33%
Radiation Therapy
30%
Confidence Interval
25%
Radiotherapy
22%
Prostate Cancer
19%
Proton Therapy
17%
Stereotactic Body Radiation Therapy
17%
Proton Beam Therapy
16%
Stereotactic Ablative Radiotherapy
16%
Local Failure
15%
Hazard Ratio
14%
Tumor
13%
Local Control
13%
Single Institution
11%
Lung Cancer
11%
Localized Prostate Cancer
11%
Concurrent Chemotherapy
11%
Stereotactic Body Radiotherapy
11%
Low-dose Radiation
11%
Chemoradiation
11%
Definitive Radiotherapy
10%
Intensity-modulated Proton Therapy
10%
Metastatic Disease
10%
Phase II Trial
10%
Median Overall Survival
9%
Dose Escalation
8%
Progression-free Survival
8%
Radiation Pneumonitis
8%
Simultaneous Integrated Boost
8%
Prostate Radiotherapy
8%
Lung
8%
Clinical Outcomes
8%
Disease-free Survival
8%
Intensity-modulated Radiation Therapy
8%
Systemic Therapy
7%
Immunoradiotherapy
7%
Spinal Metastasis
7%
Pembrolizumab
7%
Anti-PD-1
7%
Esophageal Adenocarcinoma
7%
External Beam Radiotherapy
7%
High Risk
7%
NBTXR3
7%
Definitive Chemoradiation
6%
Renal Cell Carcinoma
6%
Secondary Tumor
6%
Primary Tumor
6%
Gross Tumor Volume
6%
Chemoradiotherapy
6%